



Policy Number: PA-035 Last Review Date: 11/14/2019 Effective Date: 01/01/2020

## **Policy**

Evolent Health considers **External Insulin Pumps** medically necessary for the following indications:

- The member has completed a comprehensive diabetes and self-management educational program AND
- 2. The member has been on a program of multiple daily injections of insulin (i.e., at least three insulin injections per day) with frequent self-administration of insulin for at least six months prior to the initiation of the external insulin pump OR

The member has documented blood glucose self-testing on an average of at least four times per day, for two months prior to the initiation of the external insulin pump

- AND
- 3. The member meets at least one of the following criteria while on the multiple daily injection program:
  - a. History of severe glycemic excursions (including history of reoccurring hypoglycemia)
  - b. Glycoslated hemoglobin level (HbA1C) greater than 7.0%,
  - c. Wide fluctuations in blood glucose before or after mealtime
  - d. Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dl.
  - e. For pre-conception or pregnant members, the injections will reduce incidence of fetal mortality or anomaly

### **Continued Coverage of an external insulin pump and supplies:**

- 1. Requires that the member be seen and evaluated by the treating physician at least every three months.
- 2. The external insulin infusion pump must be ordered and follow-up care rendered by a physician who manages multiple patients on continuous subcutaneous insulin infusion therapy, and who works closely with a team including nurses, diabetic educators, and dieticians who are knowledgeable and trained in the use of continuous subcutaneous insulin infusion therapy.

#### Limitations

1. Members are limited to one pump (one brand) per warranty period of the first pump.



# **External Insulin Pumps**

Policy Number: PA-035 Last Review Date: 11/14/2019 Effective Date: 01/01/2020

- 2. Implantable insulin pumps coverage varies according to the member's benefit plan.
- 3. Chronic Intermittent Intravenous Insulin Therapy (CIIIT) is considered experimental and investigational, and therefore not covered.
- 4. V-Go disposable insulin delivery devices are considered experimental and investigational, and therefore not covered.

#### See Also:

PA-010 – Durable Medical Equipment and Corrective Appliances

### **Background**

Diabetes Mellitus is one of the leading causes of death in the United States and it is estimated that over 29 million of the United States population has diabetes. Diabetes management is related to how the body can maintain blood glucose levels near or within the normal range. Inadequate insulin production can cause elevated blood glucose levels. External insulin pumps can deliver short-acting and regular insulin needs. The battery-operated external insulin pump can be programmed to deliver the proper insulin needs.

#### Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes		
Code	Description	
A9274	External ambulatory insulin delivery system, disposable, each, includes all supplies and accessories	
E0784	External ambulatory infusion pump, insulin	
A4230	Infusion set for external insulin pump, non-needle cannula type	
A4231	Infusion set for external insulin pump, needle type	
A4232	Syringe with needle for external insulin pump, sterile, 3 cc	
K0552	Supplies for external drug infusion pump, syringe type, cartridge, sterile, each	
K0601	Replacement battery for external insulin pump owned by patient, silver oxide, 1.5 volt, each	
K0602	Replacement battery for external insulin pump owned by patient, silver oxide, 3 volt, each	
K0603	Replacement battery for external insulin pump owned by patient, alkaline, 1.5 volt, each	



# **External Insulin Pumps**

Policy Number: PA-035 Last Review Date: 11/14/2019 Effective Date: 01/01/2020

K0604	Replacement battery for external insulin pump owned by patient, lithium, 3.6 volt, each
K0605	Replacement battery for external insulin pump owned by patient, lithium, 4.5 volt, each
ICD-10 codes covered if selection criteria are met:	
E08-E09	Diabetes mellitus due to underlying condition
E10-E10.9	Type 1 diabetes mellitus
E11-E11.9	Type 2 diabetes mellitus
E13-E13.9	Other specified diabetes mellitus

#### References

- American Diabetes Association. Diabetes Basics –Statistics about Diabetes. Last reviewed March 22, 2018. <a href="http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav">http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav</a>

- Danne T, Lange K, Kordonouri O: New developments in the treatment of type I diabetes in children. Arch Dis Child. 2007 Nov; 92(11):1015-1019. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2083598/pdf/1015.pdf">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2083598/pdf/1015.pdf</a>
- 5. Eugster EA, Francis G, Lawson-Wilkins Drug and Therapeutics Committee. Position statement: Continuous subcutaneous insulin infusion in very young children with type I diabetes. Pediatrics. 2006 Oct; 118(4):e1244-e1249. <a href="http://pediatrics.aappublications.org/content/118/4/e1244.full.pdf+html">http://pediatrics.aappublications.org/content/118/4/e1244.full.pdf+html</a>
- 6. Fox LA, Buckloh LM, Smith SD, et al: A randomized controlled trial of insulin pump therapy in young children with type I diabetes. ,Diabetes Care. 2005 Jun; 28(6):1277-1281. <a href="http://care.diabetesjournals.org/content/28/6/1277.full.pdf+html">http://care.diabetesjournals.org/content/28/6/1277.full.pdf+html</a>
- Hayes. Medical Technology Directory. Insulin Pumps, External. Archived Nov 12, 2008.



# **External Insulin Pumps**

Policy Number: PA-035 Last Review Date: 11/14/2019 Effective Date: 01/01/2020

- 8. Munshi MN, Hayes M, Sternhal A, et al: Use of serum C-Peptide levels to simplify diabetes treatment regimens in older adults. The American Journal of Medicine. 2009; 122:395-397.
- WebMD. Diabetes Health Center. Diabetes and Morning High Blood Sugar. Source: American Diabetes Association. Reviewed: April 23, 2017. http://diabetes.webmd.com/morning-high-blood-sugar-levels

### Disclaimer:

Evolent Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Evolent Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Evolent Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.